Literature DB >> 16343491

A caldesmon peptide activates smooth muscle via a mechanism similar to ERK-mediated phosphorylation.

Renjian Huang1, C-L Albert Wang.   

Abstract

Caldesmon (CaD) is thought to regulate smooth muscle contraction, because it binds actin and inhibits actomyosin interactions. A synthetic actin-binding peptide (GS17C) corresponding to Gly666-Ser682 of chicken gizzard CaD has been shown to induce force development in permeabilized smooth muscle cells. The mechanism of GS17C's action remains unclear, although a structural effect was postulated. By photo-crosslinking and fluorescence quenching experiments with a gizzard CaD fragment (H32K; Met563-Pro771) and its mutants, we showed that GS17C indeed dissociated the C-terminal region of H32K from actin, in a manner similar to extracellular signal-regulated kinase-mediated phosphorylation, thereby reversing the CaD-imposed inhibition and enabling the actomyosin interaction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343491     DOI: 10.1016/j.febslet.2005.11.047

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Ablation of smooth muscle caldesmon affects the relaxation kinetics of arterial muscle.

Authors:  Hongqiu Guo; Renjian Huang; Shingo Semba; Jolanta Kordowska; Yang Hoon Huh; Yana Khalina-Stackpole; Katsuhide Mabuchi; Toshio Kitazawa; Chih-Lueh Albert Wang
Journal:  Pflugers Arch       Date:  2012-11-14       Impact factor: 3.657

2.  Effect of l-caldesmon on osteoclastogenesis in RANKL-induced RAW264.7 cells.

Authors:  Ying-Ming Liou; Chu-Lung Chan; Renjian Huang; Chih-Lueh A Wang
Journal:  J Cell Physiol       Date:  2018-03-25       Impact factor: 6.384

3.  Unraveling endothelin-1 induced hypercontractility of human pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension.

Authors:  Jamie L Wilson; Rod Warburton; Linda Taylor; Deniz Toksoz; Nicholas Hill; Peter Polgar
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.